摘要
目的 对于慢性乙型肝炎抗病毒治疗,选用恩替卡韦与干扰素分别应用的方式进行治疗,观察其实验效果.方法将2014年8月至2015年12月入院的131例慢性乙型肝炎患随机分为两组,一组为对照组,共计65例给予患者干扰素α--2b进行治疗;另一组为实验组,共计66例给予患者恩替卡韦进行治疗.观察两组患者的实际应用情况.结果 实验组在经过治疗之后,其在6、12个月中的 HBV-DNA转阴率、血清 ALT 复常率均高于对照组,两组之间存在统计学意义即 P〈0.05,而其中的HBeAg阴转率实验数据进行比较之后,两组之间并无明显的差异,不存在统计学意义（P〉0.05）.结论 使用恩替卡韦对乙型肝炎患者进行抗病毒治疗能快速抑制病毒复制并且安全性、耐受性较好,是目前一种快速有效的治疗方法.
Objective To observe the treatment of chronic hepatitis b antiviral therapy by using entecavir and interferon respec-tively,and observe its experimental results.Methods From August 2014 to December 2015,131 cases of chronic hepatitis b were randomly divided into two groups,one group was the control group and 65 patients were treated with interferon alpha-2b.In the other group,66 patients were treated with entecavir.To observe the actual application of the two groups.Results The experimental group after treatment,the HBV-DNA in 6 and 12 months turn rate,serum ALT after often rates are higher than the control group, there is statistical significance between two groups of the P〈0.05,while the rate of HBeAg Yin turn after comparing the experi-mental data,and no obvious difference between two groups,there is no statistical significance （P〉0.05）.Conclusion The antiviral treatment of patients with hepatitis b with entecavir can quickly inhibit virus replication and is safe and tolerable.It is a rapid and effective treatment.
出处
《检验医学与临床》
CAS
2017年第A02期204-205,共2页
Laboratory Medicine and Clinic
